1. Scrip

Allergan’s Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks

 
• By Mandy Jackson

With a US FDA endorsement, the drug – soon to join AbbVie’s portfolio under the companies’ $63bn merger – is the first oral option in its class and the first CGRP inhibitor approved to stop a migraine when it strikes.

FDA Approved
The US FDA approved Allergan's oral CGRP inhibitor Ubrelvy on 23 December.

Allergan PLC’s oral calcitonin gene-related peptide (CGRP) inhibitor Ubrelvy (ubrogepant) will be the first oral CGRP inhibitor to reach any market and it is the first drug in its class indicated to stop a migraine headache after it starts following the drug’s 23 December approval by the US Food and Drug Administration.

All three monoclonal antibodies against CGRP that are available in the US – Amgen Inc./Novartis AG’s Aimovig (erenumab), Teva Pharmaceutical Industries Ltd.’s Ajovy (fremanezumab) and Eli Lilly & Co.’s Emgality (galcanezumab) are approved for migraine prophylaxis, not for acute (on-demand) treatment of migraine attacks. But while Ubrelvy gives Allergan and its acquirer AbbVie Inc

More from New Products

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.